Kim Connelly
Unity Health Toronto
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Kim Connelly as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:09 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07695090 · Lumacaftor Yields Reversal of Impaired Cerebral Blood Flow in Heart Failure PatientsQanatpharma AG · recruiting · Heart Failure With Reduced Ejection Fraction · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:09 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:09 UTC. The ranking covers the 200 most relevant of 43 PubMed records, and a shared surname and initials can bring in a namesake. All 43 on PubMed
- 455 citationsRCR 20.2
- 305 citationsRCR 12.3
- SGLT2 Inhibition with Empagliflozin Increases Circulating Provascular Progenitor Cells in People with Type 2 Diabetes Mellitus.Cell Metab · 201998 citationsRCR 3.9
- Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines.Eur Heart J Cardiovasc Pharmacother · 202394 citationsRCR 8.7
- Empagliflozin Reduces Myocardial Extracellular Volume in Patients With Type 2 Diabetes and Coronary Artery Disease.JACC Cardiovasc Imaging · 202188 citationsRCR 5.4
- Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart Failure.J Am Coll Cardiol · 202547 citationsRCR 12.3
- 45 citationsRCR 1.4
- Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial.Circulation · 202333 citationsRCR 3.2
- Impact of empagliflozin on right ventricular parameters and function among patients with type 2 diabetes.Cardiovasc Diabetol · 202127 citationsRCR 1.6
- 26 citationsRCR 3.7